The Defense Health Agency awarded $835,087 to Iris Medicine, Inc. on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support amyotrophic lateral sclerosis research. Performance will take place in Berkeley, California, over a period of performance from November 1, 2026, through October 31, 2028. The Military Medical Research and Development program funds basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative research and to investigate medical solutions for battlefield use.